Osmopak Plus
Natural health product licensed in Canada
- Licence holder
- Teva Canada Limited
- NPN or DIN-HM
- 00385387
- Status
- Active licence
- Licence date
- 16 November 2007
- Revision date
- 20 December 2022
- Form
- Onguent
- Route of administration
- Topique
- Application type
- DIN de transition
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| Sulfate de magnésium Source : Minérale | 60 % |
Non-medicinal ingredients
Eau purifiée, FD&C Yellow No. 5, Hydroxyethyl Cellulose, propylèneglycol, perfume essential oil A
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et enfants | minimum: 2 years | Not specified | Not specified |
Uses authorised in Canada
Text supplied in English because no French text is available.
For treatment of inflamed area or infected subcutaneous tissue.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 00385387
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2022. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.